Christopher S Morello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1491509/publications.pdf

Version: 2024-02-01

17 papers	679 citations	13 h-index	993246 17 g-index
17	17	17	993
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge. PLoS Neglected Tropical Diseases, 2022, 16, e0010588.	1.3	2
2	Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus. PLoS Neglected Tropical Diseases, 2021, 15, e0009195.	1.3	14
3	A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2. Vaccine, 2020, 38, 79-89.	1.7	4
4	Trehalose, an mTOR-Independent Inducer of Autophagy, Inhibits Human Cytomegalovirus Infection in Multiple Cell Types. Journal of Virology, 2016, 90, 1259-1277.	1.5	60
5	25-Hydroxycholesterol Activates the Integrated Stress Response to Reprogram Transcription and Translation in Macrophages. Journal of Biological Chemistry, 2013, 288, 35812-35823.	1.6	64
6	Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood, 2012, 119, 2293-2301.	0.6	48
7	Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine, 2012, 30, 6541-6550.	1.7	24
8	Immunization with Herpes Simplex Virus 2 (HSV-2) Genes plus Inactivated HSV-2 Is Highly Protective against Acute and Recurrent HSV-2 Disease. Journal of Virology, 2011, 85, 3461-3472.	1.5	34
9	Development of Cell Lines That Provide Tightly Controlled Temporal Translation of the Human Cytomegalovirus IE2 Proteins for Complementation and Functional Analyses of Growth-Impaired and Nonviable IE2 Mutant Viruses. Journal of Virology, 2008, 82, 7059-7077.	1.5	22
10	DNA Immunization Using Highly Conserved Murine Cytomegalovirus Genes Encoding Homologs of Human Cytomegalovirus UL54 (DNA Polymerase) and UL105 (Helicase) Elicits Strong CD8 T-Cell Responses and Is Protective against Systemic Challenge. Journal of Virology, 2007, 81, 7766-7775.	1.5	26
11	Genome-Wide Analysis Reveals a Highly Diverse CD8 T Cell Response to Murine Cytomegalovirus. Journal of Immunology, 2006, 176, 3760-3766.	0.4	136
12	Systemic Priming-Boosting Immunization with a Trivalent Plasmid DNA and Inactivated Murine Cytomegalovirus (MCMV) Vaccine Provides Long-Term Protection against Viral Replication following Systemic or Mucosal MCMV Challenge. Journal of Virology, 2005, 79, 159-175.	1.5	35
13	Multiple Epitopes in the Murine Cytomegalovirus Early Gene Product M84 Are Efficiently Presented in Infected Primary Macrophages and Contribute to Strong CD8 + -T-Lymphocyte Responses and Protection following DNA Immunization. Journal of Virology, 2004, 78, 11233-11245.	1.5	13
14	Development of a Vaccine against Murine Cytomegalovirus (MCMV), Consisting of Plasmid DNA and Formalin-Inactivated MCMV, That Provides Long-Term, Complete Protection against Viral Replication. Journal of Virology, 2002, 76, 4822-4835.	1.5	46
15	Strong CD8 T-Cell Responses following Coimmunization with Plasmids Expressing the Dominant pp89 and Subdominant M84 Antigens of Murine Cytomegalovirus Correlate with Long-Term Protection against Subsequent Viral Challenge. Journal of Virology, 2002, 76, 2100-2112.	1.5	41
16	Suppression of Murine Cytomegalovirus (MCMV) Replication with a DNA Vaccine Encoding MCMV M84 (a Homolog of Human Cytomegalovirus pp65). Journal of Virology, 2000, 74, 3696-3708.	1.5	65
17	In Vivo Replication, Latency, and Immunogenicity of Murine Cytomegalovirus Mutants with Deletions in the M83 and M84 Genes, the Putative Homologs of Human Cytomegalovirus pp65 (UL83). Journal of Virology, 1999, 73, 7678-7693.	1.5	45